A new single-dose antiviral drug has been developed against orthopoxvirus that was safely tolerated in humans during phase I trials and could potentially be used to prevent and treat smallpox. Prior to eradication, variola virus, the causative agent of smallpox and member of the orthopoxvirus family, was estimated to have killed, crippled, or disfigured up to 10% of the human population.